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Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed
primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize
MHC class I molecules (KIR-ligands) as ligands. We have reported associations of KIRs and
KIR-ligands for patients in two monoclonal antibody (mAb)-based trials: (1) A Children’s
Oncology Group (COG) trial for children with high-risk neuroblastoma randomized to
immunotherapy treatment with dinutuximab (anti-GD2 mAb) + GM-CSF + IL-2 + isotretinion or to treatment with isotretinoin alone and (2) An Eastern Cooperative Oncology
Group (ECOG) trial for adults with low-tumor burden follicular lymphoma responding
to an induction course of rituximab (anti-CD20 mAb) and randomized to treatment
with maintenance rituximab or no-maintenance rituximab. In each trial, certain KIR/
KIR-ligand genotypes were associated with clinical benefit for patients randomized
to immunotherapy treatment (immunotherapy in COG; maintenance rituximab in
ECOG) as compared to patients that did not receive the immunotherapy [isotretinoin
alone (COG); no-maintenance (ECOG)]. Namely, patients with both KIR3DL1 and its
HLA-Bw4 ligand (KIR3DL1+/HLA-Bw4+ genotype) had improved clinical outcomes if
randomized to immunotherapy regimens, as compared to patients with the KIR3DL1+/
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HLA-Bw4+ genotype randomized to the non-immunotherapy regimen. Conversely,
patients that did not have the KIR3DL1+/HLA-Bw4+ genotype showed no evidence of
a difference in outcome if receiving the immunotherapy vs. no-immunotherapy. For each
trial, HLA-Bw4 status was determined by assessing the genotypes of three separate
isoforms of HLA-Bw4: (1) HLA-B-Bw4 with threonine at amino acid 80 (B-Bw4-T80);
(2) HLA-B-Bw4 with isoleucine at amino acid 80 (HLA-B-Bw4-I80); and (3) HLA-A with
a Bw4 epitope (HLA-A-Bw4). Here, we report on associations with clinical outcome
for patients with KIR3DL1 and these separate isoforms of HLA-Bw4. Patients randomized to immunotherapy with KIR3DL1+/A-Bw4+ or with KIR3DL1+/B-Bw4-T80+ had
better outcome vs. those randomized to no-immunotherapy, whereas for those with
KIR3DL1+/B-Bw4-I80+ there was no evidence of a difference based on immunotherapy
vs. no-immunotherapy. Additionally, we observed differences within treatment types
(either within immunotherapy or no-immunotherapy) that were associated with the genotype status for the different KIR3DL1/HLA-Bw4-isoforms. These studies suggest that
specific HLA-Bw4 isoforms may differentially influence response to these mAb-based
immunotherapy, further confirming the involvement of KIR-bearing cells in tumor-reactive
mAb-based cancer immunotherapy.
Keywords: KIR, KIR-ligand, HLA-Bw4, HLA, MHC class I, natural killer cells, cancer immunotherapy

and KIR-ligands can influence clinical outcome of certain cancer
immunotherapies (8, 11, 17–19). We recently showed in two clinical
trials that KIR3DL1 and its KIR-ligand, HLA-Bw4, appear to
influence clinical outcome.
In a phase III trial (ANBL0032) of high-risk neuroblastoma
patients, conducted by the Children’s Oncology Group (COG)
(1), patients who inherited the KIR3DL1 gene and the gene for
its HLA-Bw4 ligand (KIR3DL1+/Bw4+ genotype) and were
treated with an immunotherapy regimen [dinutuximab (antiGD2), IL-2, GM-CSF, and isotretinoin] had improved event-free
survival (EFS) and overall survival as compared to those treated
with isotretinoin alone (20, 21). In a separate Eastern Cooperative
Oncology Group (ECOG) Phase III clinical trial of low-tumor
burden FL (2), patients who were KIR3DL1+/HLA-Bw4+ and
treated with a continuous regimen of maintenance rituximab had
improved duration of response and % tumor shrinkage compared to
KIR3DL1+/HLA-Bw4+ patients who were randomized to not
receive maintenance rituximab (22, 23). Conversely, we did not
observe improved outcome for patients that were not KIR3DL1+/
HLA-Bw4+ when randomized to immunotherapy, in either study
(22, 23). Furthermore, in both the COG and ECOG studies,
patients who were randomized to the immunotherapy regimen
that were KIR3DL1+/HLA-Bw4+ had better outcome compared
to patients who were not KIR3DL1+/HLA-Bw4+.
Given these similar associations with outcome for the
KIR3DL1/HLA-Bw4 interaction in these two clinical trials, we
chose to evaluate these more deeply by evaluating the potential
influence of distinct HLA-Bw4 isoforms. Polymorphisms in the
α1 helix (positions 77–83) of HLA class I correspond to the
sequence site of the Bw4 epitope that is recognized by KIR3DL1
(24). In KIR/KIR-ligand associations, we analyzed in these
COG and ECOG trials, individuals were considered positive for
HLA-Bw4 if they were found to have at least one of the three

INTRODUCTION
One modality of cancer immunotherapy utilizes tumor-reactive
monoclonal antibodies (mAbs) to elicit a tumor-targeted immune
response. Two recently completed clinical trials, in separate disease settings, utilized tumor-reactive mAbs to successfully target
and treat the tumors: (1) the combination of dinutuximab with
IL-2, GM-CSF, and isotretinoin for patients with high-risk neuroblastoma (1) and (2) rituximab for the treatment of patients with
low-tumor burden follicular lymphoma (FL) (2).
Natural killer (NK) cells can contribute to the response to tumorreactive mAb-based immunotherapeutics through antibodydependent cellular cytotoxicity (ADCC). The ability of NK cells
to elicit ADCC is regulated by activating and inhibiting signaling.
Killer-cell immunoglobulin-like receptors (KIRs) are a class of
receptors expressed on NK cells that influence such signaling (3, 4).
Most inhibitory KIRs interact with HLA class I molecules as their
ligands (KIR-ligand) (5). Specifically, KIR2DL1 binds to HLAC2, KIR2DL2 and KIR2DL3 bind to HLA-C1, and KIR3DL1
recognizes the Bw4 epitope of HLA-A and HLA-B (6, 7).
The independent segregation and inheritance of KIRs and KIRligands help to shape NK cell function and response to immunotherapeutic agents (8–11). When inhibitory KIRs interact
with class I HLA molecules on target cells, NK cell-mediated
lysis and ADCC are inhibited. During development, KIR/KIRligand interactions lead to self tolerance and NK cells become
“licensed NK cells” (12–14). Licensed NK cells have augmented
cytotoxicity against class I negative tumors compared to unlicensed NK cells (15, 16).
Killer-cell immunoglobulin-like receptors and KIR-ligands
segregate independently: KIR genes are located on chromosome
19; HLA genes (KIR-ligands) are located on chromosome 6.
Several studies have shown that genotypic differences of KIR
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isoforms of HLA-Bw4: (1) HLA-B allele with a threonine at
amino acid position 80 (B-Bw4-T80), (2) HLA-B allele with
an isoleucine at amino acid position 80 (B-Bw4-I80), or (3)
HLA-A with a Bw4 epitope (A-Bw4). Patients were negative
for HLA-Bw4 if they did not have any of these three isoforms.
These polymorphisms of this Bw4 epitope can impact KIR3DL1
recognition (25–29). As such, we describe the impact of the
genotype status of B-Bw4-T80, B-Bw4-I80, and A-Bw4, together
with the genotype status of KIR3DL1, on the clinical outcome,
based on a clinical outcome parameter that measured the duration of response to the treatment regimen (EFS in COG; duration
of response in ECOG).

Olerup, West Chester, PA, USA) with GoTaq DNA polymerase
(M8295, Promega, WI, USA). All genotyping was conducted in a
blinded manner, whereby individuals who determined the genotype of the patients did not have access to the clinical outcome
data.

Statistical Methods

The goal of these analyses was to evaluate the association of
KIR3DL1 in combination with each HLA-Bw4 isoform (B-Bw4T80, B-Bw4-I80, and A-Bw4) on response to therapy (EFS or
duration of response). For the COG trial, EFS time was defined
as the time from study enrollment until the first occurrence of
relapse, progressive disease, secondary cancer, or death or until
the last contact with the patient if none of these events occurred
(censored). For the ECOG trial, the duration of response was
defined as the time from randomization (following an initial
response to the induction rituximab treatment) to documented
disease progression (2).
Cox proportional hazards regression models and log-rank tests
were used to compare EFS/duration of response curves by treatment
and genotype combinations. The proportional hazards assumption
was tested, and when the assumption was not met, adjustments
were made by incorporating time-dependent covariates into the
model. For both trials, only randomized patients were included in
the analyses. Statistical analyses were performed using SAS v9.4
(SAS Institute, Cary, NC, USA).

MATERIALS AND METHODS
Patients

COG ANBL0032 Patients

The phase III neuroblastoma clinical trial (ANBL0032;
Clinicaltrials.gov # NCT00026312) evaluated the efficacy of
isotretinoin alone as compared to an immunotherapeutic regimen consisting of dinutuximab (anti-GD2), aldesleukin (IL-2),
sargramostim (GM-CSF), and isotretinoin (1). Of the 226
patients randomized, 174 patients (immunotherapy: n = 88;
isotretinoin: n = 86) had DNA available, allowing evaluation of
KIR/KIR-ligand genotype association with updated clinical outcome (>5-year follow-up if no event). All analyses in this study
were conducted utilizing an intent-to-treat approach. All patients
signed IRB approved consent forms enabling lab-based immune
correlative analyses, and the genotyping done at UW-Madison
was approved by the UW-IRB.

RESULTS
HLA-Bw4 Isoforms, Together with
KIR3DL1, Differentially Influence the
Impact of mAb-Based Immunotherapy
on Clinical Outcome of Neuroblastoma
Patients

ECOG E4402 Patients

The Phase III ECOG clinical trial (E4402; ClinicalTrials.gov
#NCT00075946) evaluated the efficacy of single agent, rituximab
therapy for adults with low-tumor burden FL. Clinical results
from this study have been reported elsewhere (2). A total of 408
patients with FL were entered, with 289 patients responding and
randomized to no-maintenance or maintenance rituximab regimens. Disease measurements were obtained every 13 weeks (2).
Of the 289 randomized patients from this trial, 213 patients had
evaluable DNA and clinical data for this study, and 159 of them
were randomized to no-maintenance (n = 80) or maintenance
rituximab (n = 79) treatment. Of these 79 patients treated with
maintenance rituximab, 75 patients had clinical data available
for duration of response. All patients signed IRB approved
consent forms enabling lab-based immune correlative analyses,
and the genotyping done at UW-Madison was approved by the
UW-IRB.

In our analyses of associations of KIR/KIR-ligand genotypic
influence on clinical response in the neuroblastoma study
(ANBL0032), we reported on differences in clinical outcome for
those KIR3DL1+/Bw4+ (immunotherapy n = 58; isotretinoin
n = 61) and those not KIR3DL1+/Bw4+ (immunotherapy n = 30;
isotretinoin n = 25), and differences in response were observed
dependent upon treatment type (20, 21). Since not all of the
isoforms of HLA-Bw4 may interact with KIR3DL1 to the same
degree, we further assessed patients with different HLA-Bw4
isoforms in this setting.
To better understand the KIR/KIR-ligand genotypic influence
on clinical outcome, we evaluated the effect of Bw4 epitope on
either an HLA-A or HLA-B allele. In this study, patients who
were KIR3DL1+/A-Bw4+ had a trend toward improved EFS if
they were treated with immunotherapy as compared to those
treated with isotretinoin alone (p = 0.06; Figure 1A) (Table S1 in
Supplementary Material). In contrast, we did not find a significant
difference in EFS for patients receiving the immunotherapy vs.
those randomized to not receive the immunotherapy (i.e., isotretinoin alone) in the patients that were not KIR3DL1+/A-Bw4+
(p = 0.35; Figure 1A).

Genotyping

KIR3DL1 gene status was determined by a SYBR green real-time
PCR reaction (30, 31). The genotype for HLA-Bw4, which includes
three known HLA-Bw4 epitopes (B-Bw4-T80, B-Bw4-I80, and
A-Bw4) were determined by PCR-SSP reactions using the KIR
HLA Ligand SSP typing kit (product number 104.201-12u from
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Figure 1 | KIR3DL1/HLA-Bw4 isoforms differentially influence event-free survival (EFS) in neuroblastoma patients. In neuroblastoma patients treated with
immunotherapy (black lines) or isotretinoin alone (red lines), genotype statuses of KIR3DL1/A-Bw4 (A), KIR3DL1/B-Bw4-T80 (B), and KIR3DL1/B-Bw4-I80 (C) had
differential effects on EFS. Those with the genes present are represented by solid lines, and those without the genes present are represented by dotted lines. The
number of patients at risk for EFS at a given time point are provided below the x-axis. *p < 0.5 and #p < 0.10.

We found that B-Bw4-T80 and B-Bw4-I80 differentially influenced
EFS in these neuroblastoma patients (Table S1 in Supplementary
Material). Similar to results in Figure 1A, patients who were
KIR3DL1+/B-Bw4-T80+ showed significantly improved EFS if
they received immunotherapy compared with isotretinoin alone
(p = 0.04; Figure 1B), whereas those that were not KIR3DL1+/BBw4-T80+ showed no difference in EFS for patients receiving the
immunotherapy vs. those randomized to receive isotretinoin alone
(p = 0.57; Figure 1B). However, for B-Bw4-I80+, the results were
converse. Patients who were KIR3DL1+/B-Bw4-I80+ showed no
sign of improved EFS if they received immunotherapy compared
with isotretinoin alone (p = 0.60; Figure 1C). Furthermore, and
in contrast to results in Figures 1A,B, while not significant,
there appears to be improved EFS for patients receiving the
immunotherapy vs. isotretinoin alone in the patients who were
not KIR3DL1+/B-Bw4-I80+ (p = 0.10; Figure 1C).
Frontiers in Immunology | www.frontiersin.org

These findings suggest that the different isoforms of HLA-Bw4
differentially influence the impact of anti-GD2-based immunotherapy on EFS for high-risk neuroblastoma patients.

HLA-Bw4 Isoforms, Together with
KIR3DL1, Differentially Influence the
Impact of mAb-Based Immunotherapy
on Clinical Outcome of FL Patients

The ECOG E4402 Phase III clinical trial sought to optimize the
rituximab treatment regimen for low-tumor burden FL patients
(2). As such, different from the design of the neuroblastoma COG
trial described above where one treatment arm was treated with
immunotherapy and the other was not, in E4402 all patients
were initially treated with rituximab. In E4402, all FL patients
received induction rituximab, consisting of four weekly rituximab
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treatments. After 13 weeks, those patients who achieved ≥50%
tumor shrinkage were randomized to two separate treatment
regimens: (1) “maintenance” rituximab was given every 13 weeks
or (2) “no-maintenance” where rituximab was given only upon
disease progression (2). Thus, for the parameter of disease
progression, the no-maintenance group received no rituximab
between randomization and disease progression. Similar to the
COG findings regarding the genotype status of KIR3DL1/Bw4,
in this ECOG study, we also found that those KIR3DL1+/Bw4+
(maintenance n = 49; no-maintenance n = 53) had different
clinical outcome than those not KIR3DL1+/Bw4+ (maintenance
n = 27; no-maintenance n = 26), which was also influenced by the
treatment arm.
Analyses of the three separate HLA-Bw4 isoforms suggest that
the isoforms of HLA-Bw4 differently influenced the impact of maintenance rituximab. FL patients who were KIR3DL1+/A-Bw4+ that
A

were treated with maintenance rituximab had a longer duration of
response (0 of 23 progressed, Figure 2A) as compared to patients
who were not KIR3DL1+/A-Bw4+ [13 out of 53 progressed
(p = 0.008, Figure 2A) (Table S1 in Supplementary Material)].
Separately, patients who were KIR3DL1+/B-Bw4-T80+ also
showed significantly prolonged duration of response if they
received maintenance as compared with no-maintenance
rituximab (p = 0.007; Figure 2B). In addition, those patients
whowere not KIR3DL1+/B-Bw4-T80+ had a trend toward
improved duration of response if treated with maintenance as
compared with no-maintenance rituximab (p = 0.07; Figure 2B)
(Table S1 in Supplementary Material). However, patients who
were KIR3DL1+/B-Bw4-I80+ did not show prolonged duration
of response if they received maintenance as compared with nomaintenance rituximab (p = 0.40; Figure 2C). Similar to the trends
for improved EFS observed in neuroblastoma patients treated
B
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Figure 2 | KIR3DL1/HLA-Bw4 isoforms differentially influence duration of response in follicular lymphoma (FL) patients. In FL patients treated with maintenance
rituximab (red lines) or no-maintenance rituximab (black lines), genotype statuses of KIR3DL1/A-Bw4 (A), KIR3DL1/B-Bw4-T80 (B), and KIR3DL1/B-Bw4-I80
(C) had differential effects on duration of response. Those with the genes present are represented by solid lines, and those without the genes present are represented
by dotted lines. The number of patients at risk for duration of response at a given time point are provided below the x-axis. **p < 0.01, *p < 0.5, and #p < 0.10.
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with immunotherapy (Figure 1C), those FL patients who were
not KIR3DL1+/B-Bw4-I80+ had improved duration of response
if treated with maintenance rituximab as compared to nomaintenance (p = 0.002; Figure 2C) (Table S1 in Supplementary
Material).
These findings suggest that the different isoforms of HLA-Bw4
differentially influence the impact of rituximab maintenance
treatment for these low-tumor burden FL.

we did not observe differences in clinical outcome associated
with KIR3DL1 and HLA-Bw4 genotype status (39). The influence of FCGR polymorphisms on clinical outcome to rituximab
is variable (40–42). For the FL patients analyzed here from this
ECOG study, Kenkre and colleagues reported no association of
FCGR genotype polymorphisms with patient outcome (43). In
addition, some groups have found associations of FCGR genotype with clinical outcome for patients treated with anti-GD2
immunotherapy (8, 44, 45). For the neuroblastoma patients
from this COG trial, FCGR genotype associations with clinical
outcome are still under investigation. In addition, it has been
reported that the influence from KIR/KIR-ligand interactions
on NK cells may be affected by the affinity of the Fc portion
of different therapeutic mAb used (46), the rituximab used in
this ECOG trial and the dinutuximab used in this COG trial
have similar human IgG1 Fc components, which may also help
account for why we observed similar influences from HLA-Bw4
epitopes in these two separate studies where two different therapeutic mAbs were used.
These clinical data are consistent with the B-Bw4-I80 isoform functioning somewhat differently than the B-Bw4-T80 or
A-Bw4 isoforms, and potentially making the tumor cells less
responsive to the potential benefit of the anti-GD2 or anti-CD20
mAb-based immunotherapy. In vitro analyses have shown that
a subset of HLA-Bw4 alleles (those with an B-Bw4-I80 isoform)
show relative protection from lysis by NK cells (47, 48). The
data presented here are consistent with these in vitro results;
mAb-based immunotherapy may provide more benefit for
patients with weaker NK cell inhibition from B-Bw4-T80 or
A-Bw4, than for patients with stronger NK inhibition from
B-Bw4-I80.
Given that patients assessed in either trial could be positive
for more than one of the HLA-Bw4 epitopes, we did consider
whether the HLA-Bw4 epitopes were in linkage disequilibrium.
We found that A-Bw4 was not in linkage disequilibrium with either
B-Bw4-I80 or B-Bw4-T80 (Table S2 in Supplementary Material).
Thus, the influence that each of these HLA-Bw4 epitopes had on
the length of patient response in either trial is presumably not due
to linkage disequilibrium with each other.
We also considered whether the interaction of KIR3DL1 with
these three different HLA-Bw4 isoforms showed any association
of outcome among patients randomized to receive the immunotherapy regimens. Within the COG study, we observed a trend
for improved outcome for those KIR3DL1+/HLA-A-Bw4+ vs.
those not KIR3DL1+/HLA-A-Bw4+ (Figure 1A), and we also
observed a trend in the opposite direction for HLA-Bw4-I80,
namely, there was a trend for improved outcome for those not
KIR3DL1+/HLA-B-Bw4-I80+ vs. those who were KIR3DL1+/
HLA-B-Bw4-I80+ (Figure 1C). Although only a trend, this difference in Figure 1A and Figure 1C is consistent with differential
function of HLA-A-Bw4 and HLA-B-Bw4-I80. No significant
differences or trends were noted when we evaluated among the
FL patients randomized to receive the maintenance rituximab
regimen (Figures 2A–C).
The interaction of KIR3DL1 with the Bw4 epitope is dependent not only on the architecture of Bw4 but also on the sequence
of the bound peptide (25, 28, 49–51). Additionally, the differences

DISCUSSION
In both of these clinical trials, in separate disease settings, tumorreactive mAbs were used to treat the tumors. In the analysis of
KIR/KIR-ligand genotypes in each of these studies, we found
similar associations with outcomes based upon the influence of
KIR3DL1/HLA-Bw4. Specifically, those patients who had both
KIR3DL1 and HLA-Bw4 had improved clinical outcomes if
they were treated with either the COG immunotherapy regimen
or the maintenance rituximab regimen in ECOG as compared
to those who did not receive these same immunotherapeutic
regimens (20, 21). Here, we report on the analyses of the
specific HLA-Bw4 isoforms in both trials. In the ECOG trial
of FL patients, patients with a KIR3DL1+/A-Bw4+ genotype
or a KIR3DL1+/B-Bw4-T80+ genotype showed improved
outcome when randomized to the maintenance regimen rather
than to the no-maintenance regimen. In contrast, patients with
a KIR3DL1+/B-Bw4-I80+ genotype showed no evidence of
improved outcome when randomized to the maintenance treatment vs. no-maintenance regimen. We also observed similar
trends for these same analyses in the COG trial of neuroblastoma patients.
Although other mechanisms, such as antibody-dependent
cellular phagocytosis and complement-dependent cellular cytotoxicity (32, 33), could also contribute to the anti-tumor efficacy
of tumor antigen-specific monoclonal antibodies, we hypothesize
that the anti-tumor effect of rituximab and dinutuximab in these
FL and neuroblastoma patients, respectively, is primarily through
ADCC. NK cells are major contributors to ADCC, and their
activity is regulated via the interactions between KIRs/KIRligands (34). As such, we hypothesize that the KIR/KIR-ligand
genotypes could influence the degree that patients respond to
antibody-based immunotherapies. Besides NK cells, KIRs are
also expressed by a subset of T cells as well as NKT cells (35, 36).
Therefore, it is possible that these other cell types may also be
influenced by KIR/KIR-ligand genotypes.
Besides inherited genetic differences in KIR and KIR-ligand
genotypes, other individual genetic differences, such as polymorphisms in Fc gamma receptors (FCGRs), may influence patient
outcome to immunotherapy. FCGR polymorphisms can alter
the affinity of FCGRs for the Fc portion of antibodies (mAbs or
endogenous antibodies) (37). For example, in a separate study
of patients with metastatic renal cell carcinoma treated with
high-dose IL-2, we found that patients with a “higher affinity”
FCGR genotype had improved clinical outcome as compared
to those patients with a “lower affinity” FCGR genotype (38).
In our analysis of those same metastatic renal cell carcinoma
patients for KIR/KIR-ligand genotype influence on outcome,
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we observed between A-Bw4, B-Bw4-T80, and B-Bw4-I80 may
be due to the different inhibition strength for KIR3DL1 from
these isoforms. For instance, HLA-A*32:01, HLA-B*51:01,
and HLA-B*58:01 strongly inhibit target cells from lysis by
KIR3DL1+ NK cells, yet HLA-B*15:13 and HLA-B*27:05 have
weaker inhibitory effects, despite all being HLA-Bw4 alleles (6,
25, 26, 48, 52–54). In addition, depending on the KIR3DL1 allele,
expression of KIR3DL1 can vary; different HLA-A-Bw4 alleles
have differential affinity for KIR3DL1 that is attributed to high vs.
low expression of KIR3DL1 (55). Furthermore, the specific Bw4
allele, as well as the KIR3DL1 allele, the strength of KIR3DL1/
HLA-Bw4 interaction and the binding avidity can vary (29). For
example, Saunders et al. recently showed that HLA-A*24:02 acts
as a poor ligand for KIR3DL1, and the strength of its interaction
with KIR3DL1 differed depending on the allele of KIR3DL1 (29).
The genotyping methodology employed for analyzing the many
patients in these two clinical trials reported here was not able
to address these more subtle allele-specific or peptide-related
issues.
Another possible cause of the differences observed in these
HLA-Bw4 isoforms may be due to genetic polymorphisms of
KIR3DL1 (26, 28, 29, 56–60). More than 100 alleles of KIR3DL1
have been described. Phylogenetically, these alleles span three
lineages based on the polymorphism of the three extracellular
domains (D0–D1–D2) (53, 61). In both of these clinical studies
analyzed, we did not determine the allelic differences of the KIR
genes, but rather we determined their presence or absence. Thus,
we cannot assess how different KIR3DL1 alleles may affect the
interactions between different isoforms of HLA-Bw4. We did,
however, assess if KIR3DL1 allelic status could influence the
interactions of KIR3DL1 with HLA-Bw4 and with the separate
HLA-Bw4 isoforms. KIR3DL1 and KIR3DS1 are alleles, thus
individuals can have 2, 1, or 0 copies of KIR3DL1 (2 copies:
KIR3DL1/KIR3DL1, 1 copy: KIR3DL1/KIR3DS1, or 0 copies:
KIR3DS1/KIRDS1). Although KIR3DS1 has not been shown
to utilize HLA-Bw4 as a ligand in vitro, whether KIR3DS1 may
still interact with HLA-Bw4 in vivo is controversial (62–65).
We assessed whether the allelic status of KIR3DL1/KIR3DS1
together with HLA-Bw4 (and HLA-Bw4 isoforms) influenced
patient response. We found that there was no evidence of an
association with outcome in either the COG or the ECOG study
that could be linked to the allelic status of KIR3DL1/KIR3DLS1
(data not shown), nor was there evidence of an association of
clinical outcome linked to KIR3DL1/KIR3DS1 status together
with the HLA-Bw4 ligand isoforms (data not shown). Rather, the
mere presence of KIR3DL1 together with its ligand, HLA-Bw4,
seemed to influence patients’ response to immunotherapy in
both clinical trials. These observations will require validation in
a separate study.
In conclusion, this work sheds further light on the role of KIR
receptors on NK cells in the antitumor response to immunotherapeutic mAbs. We demonstrate that the KIR3DL1/HLA-Bw4
axis influences response to tumor-targeted mAbs in two separate
clinical trials and that the presence of the B-Bw4-T80 isoform
or the A-Bw4 isoform is associated with improved response to
mAb-based immunotherapy, while the presence of the B-Bw4-I80
isoform is not.
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